Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-trace').style.display = (document.getElementById('cakeErr68031f4a0a17c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68031f4a0a17c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-code').style.display = (document.getElementById('cakeErr68031f4a0a17c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-context').style.display = (document.getElementById('cakeErr68031f4a0a17c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68031f4a0a17c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68031f4a0a17c-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14934,
		&#039;title&#039; =&gt; &#039;Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
-PTI&lt;br /&gt;
&lt;br /&gt;
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;
&lt;br /&gt;
Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;
&lt;br /&gt;
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;
&lt;br /&gt;
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;
&lt;br /&gt;
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;
&lt;br /&gt;
The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;
&lt;br /&gt;
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;
&lt;br /&gt;
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;
&lt;br /&gt;
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;
&lt;br /&gt;
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;
&lt;br /&gt;
European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;
&lt;br /&gt;
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;
&lt;br /&gt;
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15058,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14934,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;br /&gt;&lt;br /&gt;German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;&lt;br /&gt;Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;&lt;br /&gt;Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;&lt;br /&gt;Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;&lt;br /&gt;The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;&lt;br /&gt;The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;&lt;br /&gt;Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;&lt;br /&gt;An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;&lt;br /&gt;The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;&lt;br /&gt;To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;&lt;br /&gt;The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;&lt;br /&gt;The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;&lt;br /&gt;It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;&lt;br /&gt;European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;&lt;br /&gt;They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;&lt;br /&gt;They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14934,
	&#039;title&#039; =&gt; &#039;Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
-PTI&lt;br /&gt;
&lt;br /&gt;
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;
&lt;br /&gt;
Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;
&lt;br /&gt;
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;
&lt;br /&gt;
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;
&lt;br /&gt;
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;
&lt;br /&gt;
The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;
&lt;br /&gt;
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;
&lt;br /&gt;
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;
&lt;br /&gt;
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;
&lt;br /&gt;
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;
&lt;br /&gt;
European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;
&lt;br /&gt;
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;
&lt;br /&gt;
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15058,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14934
$metaTitle = &#039;LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...&#039;
$disp = &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;br /&gt;&lt;br /&gt;German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;&lt;br /&gt;Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;&lt;br /&gt;Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;&lt;br /&gt;Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;&lt;br /&gt;The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;&lt;br /&gt;The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;&lt;br /&gt;Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;&lt;br /&gt;An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;&lt;br /&gt;The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;&lt;br /&gt;To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;&lt;br /&gt;The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;&lt;br /&gt;The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;&lt;br /&gt;It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;&lt;br /&gt;European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;&lt;br /&gt;They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;&lt;br /&gt;They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug | Im4change.org</title>
    <meta name="description" content="

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bayer to challenge Cipla’s decision to cut price of cancer drug</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <br /><div align="justify">-PTI<br /><br />German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.<br /><br />Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &ldquo;is a clear patent infringement,&rdquo; a Bayer spokesperson told PTI.<br /><br />Bayer holds the patent for Nexavar till 2020 and it would &ldquo;vigorously defend its patent within the available legal framework,&rdquo; the spokesperson said.<br /><br />Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement.<br /><br />The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.<br /><br />The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.<br /><br />Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.<br /><br />An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.<br /><br />The order of the Indian patents office &ldquo;damages the international patent system and endangers pharmaceutical research,&rdquo; the statement said. &ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&rdquo;<br /><br />The challenges faced by India&rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&rsquo;s essential drugs list are not patented, Bayer said.<br /><br />To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.<br /><br />The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.<br /><br />The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &ldquo;public interest&rdquo;.<br /><br />The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.<br /><br />It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.<br /><br />European medical relief and charity organisations have welcomed the Indian government&rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.<br /><br />They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.<br /><br />They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-trace').style.display = (document.getElementById('cakeErr68031f4a0a17c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68031f4a0a17c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-code').style.display = (document.getElementById('cakeErr68031f4a0a17c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-context').style.display = (document.getElementById('cakeErr68031f4a0a17c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68031f4a0a17c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68031f4a0a17c-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14934,
		&#039;title&#039; =&gt; &#039;Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
-PTI&lt;br /&gt;
&lt;br /&gt;
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;
&lt;br /&gt;
Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;
&lt;br /&gt;
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;
&lt;br /&gt;
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;
&lt;br /&gt;
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;
&lt;br /&gt;
The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;
&lt;br /&gt;
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;
&lt;br /&gt;
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;
&lt;br /&gt;
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;
&lt;br /&gt;
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;
&lt;br /&gt;
European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;
&lt;br /&gt;
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;
&lt;br /&gt;
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15058,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14934,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;br /&gt;&lt;br /&gt;German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;&lt;br /&gt;Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;&lt;br /&gt;Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;&lt;br /&gt;Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;&lt;br /&gt;The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;&lt;br /&gt;The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;&lt;br /&gt;Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;&lt;br /&gt;An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;&lt;br /&gt;The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;&lt;br /&gt;To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;&lt;br /&gt;The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;&lt;br /&gt;The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;&lt;br /&gt;It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;&lt;br /&gt;European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;&lt;br /&gt;They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;&lt;br /&gt;They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14934,
	&#039;title&#039; =&gt; &#039;Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
-PTI&lt;br /&gt;
&lt;br /&gt;
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;
&lt;br /&gt;
Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;
&lt;br /&gt;
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;
&lt;br /&gt;
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;
&lt;br /&gt;
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;
&lt;br /&gt;
The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;
&lt;br /&gt;
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;
&lt;br /&gt;
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;
&lt;br /&gt;
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;
&lt;br /&gt;
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;
&lt;br /&gt;
European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;
&lt;br /&gt;
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;
&lt;br /&gt;
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15058,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14934
$metaTitle = &#039;LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...&#039;
$disp = &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;br /&gt;&lt;br /&gt;German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;&lt;br /&gt;Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;&lt;br /&gt;Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;&lt;br /&gt;Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;&lt;br /&gt;The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;&lt;br /&gt;The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;&lt;br /&gt;Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;&lt;br /&gt;An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;&lt;br /&gt;The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;&lt;br /&gt;To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;&lt;br /&gt;The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;&lt;br /&gt;The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;&lt;br /&gt;It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;&lt;br /&gt;European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;&lt;br /&gt;They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;&lt;br /&gt;They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug | Im4change.org</title>
    <meta name="description" content="

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bayer to challenge Cipla’s decision to cut price of cancer drug</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <br /><div align="justify">-PTI<br /><br />German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.<br /><br />Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &ldquo;is a clear patent infringement,&rdquo; a Bayer spokesperson told PTI.<br /><br />Bayer holds the patent for Nexavar till 2020 and it would &ldquo;vigorously defend its patent within the available legal framework,&rdquo; the spokesperson said.<br /><br />Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement.<br /><br />The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.<br /><br />The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.<br /><br />Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.<br /><br />An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.<br /><br />The order of the Indian patents office &ldquo;damages the international patent system and endangers pharmaceutical research,&rdquo; the statement said. &ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&rdquo;<br /><br />The challenges faced by India&rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&rsquo;s essential drugs list are not patented, Bayer said.<br /><br />To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.<br /><br />The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.<br /><br />The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &ldquo;public interest&rdquo;.<br /><br />The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.<br /><br />It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.<br /><br />European medical relief and charity organisations have welcomed the Indian government&rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.<br /><br />They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.<br /><br />They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-trace').style.display = (document.getElementById('cakeErr68031f4a0a17c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68031f4a0a17c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-code').style.display = (document.getElementById('cakeErr68031f4a0a17c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68031f4a0a17c-context').style.display = (document.getElementById('cakeErr68031f4a0a17c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68031f4a0a17c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68031f4a0a17c-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14934,
		&#039;title&#039; =&gt; &#039;Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
-PTI&lt;br /&gt;
&lt;br /&gt;
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;
&lt;br /&gt;
Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;
&lt;br /&gt;
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;
&lt;br /&gt;
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;
&lt;br /&gt;
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;
&lt;br /&gt;
The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;
&lt;br /&gt;
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;
&lt;br /&gt;
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;
&lt;br /&gt;
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;
&lt;br /&gt;
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;
&lt;br /&gt;
European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;
&lt;br /&gt;
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;
&lt;br /&gt;
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15058,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14934,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;br /&gt;&lt;br /&gt;German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;&lt;br /&gt;Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;&lt;br /&gt;Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;&lt;br /&gt;Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;&lt;br /&gt;The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;&lt;br /&gt;The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;&lt;br /&gt;Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;&lt;br /&gt;An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;&lt;br /&gt;The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;&lt;br /&gt;To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;&lt;br /&gt;The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;&lt;br /&gt;The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;&lt;br /&gt;It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;&lt;br /&gt;European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;&lt;br /&gt;They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;&lt;br /&gt;They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14934,
	&#039;title&#039; =&gt; &#039;Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;br /&gt;
&lt;div align=&quot;justify&quot;&gt;
-PTI&lt;br /&gt;
&lt;br /&gt;
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;
&lt;br /&gt;
Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;
&lt;br /&gt;
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;
&lt;br /&gt;
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;
&lt;br /&gt;
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;
&lt;br /&gt;
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;
&lt;br /&gt;
The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;
&lt;br /&gt;
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;
&lt;br /&gt;
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;
&lt;br /&gt;
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;
&lt;br /&gt;
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;
&lt;br /&gt;
European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;
&lt;br /&gt;
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;
&lt;br /&gt;
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15058,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14934
$metaTitle = &#039;LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...&#039;
$disp = &#039;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;br /&gt;&lt;br /&gt;German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.&lt;br /&gt;&lt;br /&gt;Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&amp;rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &amp;ldquo;is a clear patent infringement,&amp;rdquo; a Bayer spokesperson told PTI.&lt;br /&gt;&lt;br /&gt;Bayer holds the patent for Nexavar till 2020 and it would &amp;ldquo;vigorously defend its patent within the available legal framework,&amp;rdquo; the spokesperson said.&lt;br /&gt;&lt;br /&gt;Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month&#039;s therapy, from Rs 6,990, Cipla had said in a statement.&lt;br /&gt;&lt;br /&gt;The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.&lt;br /&gt;&lt;br /&gt;The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.&lt;br /&gt;&lt;br /&gt;Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.&lt;br /&gt;&lt;br /&gt;An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.&lt;br /&gt;&lt;br /&gt;The order of the Indian patents office &amp;ldquo;damages the international patent system and endangers pharmaceutical research,&amp;rdquo; the statement said. &amp;ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The challenges faced by India&amp;rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&amp;rsquo;s essential drugs list are not patented, Bayer said.&lt;br /&gt;&lt;br /&gt;To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.&lt;br /&gt;&lt;br /&gt;The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.&lt;br /&gt;&lt;br /&gt;The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &amp;ldquo;public interest&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.&lt;br /&gt;&lt;br /&gt;It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.&lt;br /&gt;&lt;br /&gt;European medical relief and charity organisations have welcomed the Indian government&amp;rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.&lt;br /&gt;&lt;br /&gt;They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.&lt;br /&gt;&lt;br /&gt;They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug | Im4change.org</title>
    <meta name="description" content="

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bayer to challenge Cipla’s decision to cut price of cancer drug</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <br /><div align="justify">-PTI<br /><br />German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.<br /><br />Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &ldquo;is a clear patent infringement,&rdquo; a Bayer spokesperson told PTI.<br /><br />Bayer holds the patent for Nexavar till 2020 and it would &ldquo;vigorously defend its patent within the available legal framework,&rdquo; the spokesperson said.<br /><br />Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement.<br /><br />The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.<br /><br />The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.<br /><br />Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.<br /><br />An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.<br /><br />The order of the Indian patents office &ldquo;damages the international patent system and endangers pharmaceutical research,&rdquo; the statement said. &ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&rdquo;<br /><br />The challenges faced by India&rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&rsquo;s essential drugs list are not patented, Bayer said.<br /><br />To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.<br /><br />The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.<br /><br />The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &ldquo;public interest&rdquo;.<br /><br />The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.<br /><br />It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.<br /><br />European medical relief and charity organisations have welcomed the Indian government&rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.<br /><br />They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.<br /><br />They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 14934,
		'title' => 'Bayer to challenge Cipla’s decision to cut price of cancer drug',
		'subheading' => '',
		'description' => '<br />
<div align="justify">
-PTI<br />
<br />
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.<br />
<br />
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &ldquo;is a clear patent infringement,&rdquo; a Bayer spokesperson told PTI.<br />
<br />
Bayer holds the patent for Nexavar till 2020 and it would &ldquo;vigorously defend its patent within the available legal framework,&rdquo; the spokesperson said.<br />
<br />
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement.<br />
<br />
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.<br />
<br />
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.<br />
<br />
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.<br />
<br />
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.<br />
<br />
The order of the Indian patents office &ldquo;damages the international patent system and endangers pharmaceutical research,&rdquo; the statement said. &ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&rdquo;<br />
<br />
The challenges faced by India&rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&rsquo;s essential drugs list are not patented, Bayer said.<br />
<br />
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.<br />
<br />
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.<br />
<br />
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &ldquo;public interest&rdquo;.<br />
<br />
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.<br />
<br />
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.<br />
<br />
European medical relief and charity organisations have welcomed the Indian government&rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.<br />
<br />
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.<br />
<br />
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. <br />
</div>',
		'credit_writer' => 'The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 15058,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 14934,
	'metaTitle' => 'LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug',
	'metaKeywords' => 'medicines,Health',
	'metaDesc' => '

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...',
	'disp' => '<br /><div align="justify">-PTI<br /><br />German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.<br /><br />Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &ldquo;is a clear patent infringement,&rdquo; a Bayer spokesperson told PTI.<br /><br />Bayer holds the patent for Nexavar till 2020 and it would &ldquo;vigorously defend its patent within the available legal framework,&rdquo; the spokesperson said.<br /><br />Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement.<br /><br />The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.<br /><br />The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.<br /><br />Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.<br /><br />An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.<br /><br />The order of the Indian patents office &ldquo;damages the international patent system and endangers pharmaceutical research,&rdquo; the statement said. &ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&rdquo;<br /><br />The challenges faced by India&rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&rsquo;s essential drugs list are not patented, Bayer said.<br /><br />To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.<br /><br />The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.<br /><br />The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &ldquo;public interest&rdquo;.<br /><br />The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.<br /><br />It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.<br /><br />European medical relief and charity organisations have welcomed the Indian government&rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.<br /><br />They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.<br /><br />They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. <br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 14934,
	'title' => 'Bayer to challenge Cipla’s decision to cut price of cancer drug',
	'subheading' => '',
	'description' => '<br />
<div align="justify">
-PTI<br />
<br />
German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.<br />
<br />
Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &ldquo;is a clear patent infringement,&rdquo; a Bayer spokesperson told PTI.<br />
<br />
Bayer holds the patent for Nexavar till 2020 and it would &ldquo;vigorously defend its patent within the available legal framework,&rdquo; the spokesperson said.<br />
<br />
Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement.<br />
<br />
The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.<br />
<br />
The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.<br />
<br />
Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.<br />
<br />
An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.<br />
<br />
The order of the Indian patents office &ldquo;damages the international patent system and endangers pharmaceutical research,&rdquo; the statement said. &ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&rdquo;<br />
<br />
The challenges faced by India&rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&rsquo;s essential drugs list are not patented, Bayer said.<br />
<br />
To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.<br />
<br />
The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.<br />
<br />
The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &ldquo;public interest&rdquo;.<br />
<br />
The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.<br />
<br />
It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.<br />
<br />
European medical relief and charity organisations have welcomed the Indian government&rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.<br />
<br />
They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.<br />
<br />
They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. <br />
</div>',
	'credit_writer' => 'The Telegraph, 10 May, 2012, http://www.telegraphindia.com/1120510/jsp/frontpage/story_15473326.jsp#.T6uHRJj5nYQ',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'bayer-to-challenge-ciplas-decision-to-cut-price-of-cancer-drug-15058',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 15058,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 14934
$metaTitle = 'LATEST NEWS UPDATES | Bayer to challenge Cipla’s decision to cut price of cancer drug'
$metaKeywords = 'medicines,Health'
$metaDesc = '

-PTI

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.

Bayer Pharma has not given its consent to Cipla...'
$disp = '<br /><div align="justify">-PTI<br /><br />German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.<br /><br />Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company&rsquo;s decision to cut the price of the life-extending kidney and liver cancer drug &ldquo;is a clear patent infringement,&rdquo; a Bayer spokesperson told PTI.<br /><br />Bayer holds the patent for Nexavar till 2020 and it would &ldquo;vigorously defend its patent within the available legal framework,&rdquo; the spokesperson said.<br /><br />Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement.<br /><br />The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.<br /><br />The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said.<br /><br />Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar.<br /><br />An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement.<br /><br />The order of the Indian patents office &ldquo;damages the international patent system and endangers pharmaceutical research,&rdquo; the statement said. &ldquo;We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.&rdquo;<br /><br />The challenges faced by India&rsquo;s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India&rsquo;s essential drugs list are not patented, Bayer said.<br /><br />To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said.<br /><br />The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients.<br /><br />The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in &ldquo;public interest&rdquo;.<br /><br />The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer.<br /><br />It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis.<br /><br />European medical relief and charity organisations have welcomed the Indian government&rsquo;s decision to issue the first compulsory licence for the generic production of a patent- protected drug.<br /><br />They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public.<br /><br />They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment. <br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Bayer to challenge Cipla’s decision to cut price of cancer drug

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear patent infringement,” a Bayer spokesperson told PTI. Bayer holds the patent for Nexavar till 2020 and it would “vigorously defend its patent within the available legal framework,” the spokesperson said. Cipla had slashed by up to 76 per cent the prices of some generic drugs used in treating cancers of the brain, lung and kidney. The price of Soranib, used for treating kidney cancer, was cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla had said in a statement. The Delhi High Court is already dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India (DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar. The next hearing to decide the course of the proceedings is scheduled for August 14, 2012, the spokesperson said. Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of Nexavar. An appeal against the decision of the Controller General of Patents, Designs and Trademarks to grant a compulsory licence for Nexavar was filed with the Intellectual Property Appellate Board (IPAB) on May 4, it said in a press statement. The order of the Indian patents office “damages the international patent system and endangers pharmaceutical research,” the statement said. “We will vigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients.” The challenges faced by India’s healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India’s essential drugs list are not patented, Bayer said. To facilitate access for patients to innovative treatments, Bayer has a Patient Access Programme in place since the launch of Nexavar in India in 2008, the statement said. The Indian government invoked a trade rule of the World Trade Organisation (WTO) to issue the first compulsory licence to allow generic production of a patented drug to make it affordable to Indian patients. The Trade Related Intellectual Property Rights (Trips) agreement under the WTO allows a government to grant compulsory licence to a domestic company to produce a generic version of a patented drug in “public interest”. The patent office had asked Hyderabad-based Natco Pharma to make available Nexavar to cancer patients a monthly dose of 120 tablets for Rs 8,800 ($176) compared to Rs 2,80,000 ($5,500) charged by Bayer. It also asked Natco Pharma to pay the patent-holder a six per cent royalty on the net sales of the cancer drug on a quarterly basis. European medical relief and charity organisations have welcomed the Indian government’s decision to issue the first compulsory licence for the generic production of a patent- protected drug. They have said that such steps are necessary to make medicines not only for treating cancer, but also for HIV/AIDS and other diseases, affordable to the general public. They pointed out that the current costs of Nexavar are unaffordable for many people even in Europe and without the support from national health services, many cancer patients would not have been able to receive the treatment.